Last reviewed · How we verify
NCT06223100
Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection
trial testing Eravacycline in Immune Dysregulation Disorder in 100 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | Sichuan Provincial People's Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 February 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
Drugs / interventions tested
- Eravacycline (ERAVACYCLINE) — full drug profile →
Conditions studied
- Immune Dysregulation Disorder — all drugs for Immune Dysregulation Disorder →
Sponsor
Sichuan Provincial People's Hospital
Who can join
18 and older, any sex, with Immune Dysregulation Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to explore the treatment mode and clinical outcome of patients with immunocompromised who received the combined regimen of eraracycline in the treatment of multidrug-resistant bacterial infections, to evaluate the efficacy and safety of the combined regimen of eravacycline in the treatment of multidrug-resistant bacterial infections in immunocompromised host populations, and to provide data reference for the treatment of immunocompromised populations.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Therapeutic challenges and emerging strategies against carbapenem-resistant <i>Acinetobacter baumannii</i>.
Yang C, Li J, Luo X, Song Z, et al · · 2026 · PMID 41907167 · DOI 10.1016/j.crmicr.2026.100581
Verify or expand the search:
- PubMed search for NCT06223100
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Eravacycline
Trials testing the same drug.
- NCT02784704 — Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections · Phase 3 · completed
- NCT01978938 — Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections · Phase 3 · completed
Other Sichuan Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07298525 — Safety Exploration and Evaluation of Dexmedetomidine Hydrochloride Nasal Spray for Pre-anesthesia Sedation in Low-Monito · Phase 4 · not yet recruiting
- NCT07175363 — Butorphanol for Pain Relief After Cesarean Section: A Retrospective Study · not yet recruiting
- NCT07106996 — Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycysti · EARLY_PHASE1 · recruiting
- NCT07082946 — Mechanisms of Perioperative Systemic Inflammation in the Development of PND in Cirrhotic Patients · not yet recruiting
- NCT06821633 — Investigating the Retardation Effect of OCTA-Guided Targeted Photocoagulation on the Progression of Non-Perfusion Areas · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06223100 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan Provincial People's Hospital
- Last refreshed: 25 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06223100.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing